<DOC>
	<DOC>NCT00479557</DOC>
	<brief_summary>To assess the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in patients with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Diagnosis of probable Alzheimer's Disease with MiniMental State Examination (MMSE) score of 1626 (except Germany: 2126) Brain MRI consistent with Alzheimer Disease Concurent use of Chloniesterase inhibitor or memantine allowed if stable Other inclusion criteria apply Significant Neurological Disease other than Alzheimer's disease Major psychiatric disorder Contraindication to undergo brain MRI Clinically significant systemic illness Other exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Alzheimer's Disease</keyword>
	<keyword>active immunization</keyword>
</DOC>